Effect of Ivabradine in Stage D HF/Cardiogenic Shock Patients on Dobutamine
Status:
Unknown status
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double blind, single center trial to study of the effects of Ivabradine
vs. Placebo on patients hospitalized for Stage D heart failure (HF)/ and cardiogenic shock
(CS) who will require continuous infusion of Dobutamine and have developed sinus tachycardia
(ST) (heart rate >100 beats/min).
The aim of the study will be to assess the potential of Ivabradine to slow ST and improve
hemodynamics in patients with stage D HF/CS on Dobutamine treatment.